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Abstract 
 Tobacco products, both combustible and smokeless, contain abundant 
amounts of toxic chemicals and carcinogens capable of causing extensive damage to the 
body.  Tobacco specific nitrosamines, including 4-(methylnitrosoamino)-1-(3-pyridyl)-1-
butanone (NNK) and N’-nitrosonornicotine (NNN), are among the most potent of these 
carcinogens and are capable of eliciting cellular transformations within the body after 
bioactivation by cytochrome P450 enzymes.  In order to reduce the harm associated with 
smokeless tobacco, a recombinant anti-NNK antibody has been constructed from a 
hybridoma secreting a mouse monoclonal antibody specific for NNK.   
In work performed previously, hybridomas were created by constructing a 
structurally-related benzoyl derivative to facilitate coupling to NNK-carrier proteins, 
which were then used to immunize BALB/C mice.  Splenocytes from mice bearing NNK-
specific antibodies were used for hybridoma production and the final product was 
isolated, characterized and found to secrete a high-affinity anti-NNK monoclonal 
antibody.  In the current study, the heavy and light chain antibody F(ab) fragments were 
cloned, sequenced and inserted in tandem into an expression vector with an FMDV Furin 
2A cleavage site between them. Expression in HEK 293 cells revealed a functional F(ab) 
with similar binding features to that of the parent hybridoma. This study lays the 
groundwork for synthesizing transgenic tobacco that expresses carcinogen-sequestration 
properties, thereby rendering it less harmful to consumers. 
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Introduction 
 
 
1.1.1 Negative Health Effects of Chronic Tobacco Use 
 
Tobacco use continues to be the main cause of lung cancer and cardiovascular 
disease worldwide and has been estimated to kill more than 6 million people each year 
[1,2].  Despite decades of continuous efforts to control the production and marketing of 
tobacco products, especially to youths, countless people still engage in this dangerous 
habit [3].  On average, it has been shown that cigarette smoking can reduce the lifespan 
of an individual by 13.5 years [4].  According to the World Health Organization, 
approximately one person dies every six seconds due to tobacco use, which accounts for 
one in ten adult deaths.  The American Heart Association estimates that in 2004, tobacco 
use cost the United States $193 billion dollars in healthcare and lost productivity.  
 Over the past decade, the number of people who smoke in the United States has 
declined by a small percentage.  In 2011, the CDC estimated that there was about a 2-3% 
drop in the number of male and female smokers over a span of nine years (2000-2009).  
However, worldwide it has been estimated that there are 6 billion people who currently 
use some form of tobacco and out of this population, 80% live in low- and middle- 
income families [5].  These numbers are concerning considering that over 6,000 harmful 
chemicals and toxicants are consumed by an individual when a single cigarette is 
smoked.  Around sixty of these compounds have been classified as known or suspected 
carcinogens and include polycyclic aromatic hydrocarbons, formaldehyde, benzene and 
tobacco specific nitrosamines (TSNAs) [6,7]. 
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1.1.2 Tobacco Specific Nitrosamines 
The most abundant and potent carcinogens found within cigarettes and smokeless 
tobacco products are tobacco specific nitrosamines, 4-(methylnitrosoamino)-1-(3-
pyridyl)-1-butanone (NNK), 4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL) 
and N’-nitrosonornicotine (NNN) [8,9].  Each of these nitrosamines contains a single N’ 
nitroso moiety that is responsible for the carcinogenic nature of the compounds.  NNK 
and NNN are classified as Group 1 human carcinogens by the International Agency for 
the Research on Cancer (IARC) and are formed from the nitrosation of the tobacco 
alkaloid nicotine [10].  This process involves the interaction of nicotine with a nitrate, 
nitrite or nitrogenous gas and occurs both during the curing and processing of tobacco 
and in the mammalian organism itself [11].  N’-nitrosonornicotine (NNN) is additionally 
formed by the demethylation of nicotine into nornicotine, which is then followed by 
nitrosation of the pyrrolidine nitrogen of nornicotine. 
  Minor secondary tobacco alkaloids such as anatabine and anabasine also 
participate in the formation of tobacco specific nitrosamines, but to a lesser extent than 
nicotine (Figure 1.1).  Through reductive metabolism of NNK, NNAL is formed, which 
is another potent carcinogen [6].   It can be detected in the plasma and urine of cigarette 
users as well as people exposed to secondary smoke, making it an effective biomarker for 
the uptake of NNK.  Higher urine NNAL has been proven to coincide with poorer 
physical health, restricted activity and dyspnea, which is an early predictor of lung cancer 
susceptibility [12,13].   
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Figure 1.1 Nitrosation of Tobacco Alkaloids [14] 
 
Nitrosation of tertiary and secondary minor tobacco alkaloids results in the formation of 
Tobacco Specific Nitrosamines, some of the most potent chemicals contained within 
tobacco products. 
 
 
 
1.1.3 Metabolic Activation of TSNAs 
In order to elicit cellular transformations within the body, the nitrosamines must 
be metabolically activated by cytochrome P450 enzymes such as CYP2A6 and 
CYP2A13, integral membrane proteins located within the endoplasmic reticulum of cells 
[15].  Although both enzymes play an important role in activation, CYP2A13 has been 
shown to activate NNK with a 61- to 214- fold greater catalytic efficiency than CYP2A6 
[16-18].  Via hydroxylation pathways, NNK and NNN are metabolized into either 
methylating (7-methylguanine, O6-methylguanine) or pyridyloxobutylating (7-POB 
guanine, O2-POB thymine, O6-POB guanine) agents capable of forming DNA adducts,  
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which initiate mutations that contribute to tumor formation [8,6, 10, 19]. (Figure 1.2)  In 
the current study, NNK is focused on exclusively due to the fact that it is the most potent 
carcinogen identified in smokeless and combustible tobacco products [20]. 
 
Figure 1.2 Metabolic Activation of NNK and DNA Adduct Formation [21] 
 
Metabolic activation of NNK by Cytochrome P450 enzymes results in reactive 
intermediates that alkylate DNA.  This leads to the formation of Pyridyloxobutyl or 
Methyl DNA adducts that are responsible for the initiation of tumor development. 
 
 
 
In rodent studies, NNK has been shown to induce tumors in the lung, nasal and 
oral cavities, esophagus, liver and exocrine pancreas irrespective of the route of 
administration [8].  Further evidence for the carcinogenicity of NNK has been established 
in several in vitro studies whereby the nitrosamine induces the proliferation of normal 
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human lung epithelial cells, small cell lung cancer (SCLC) and non-small cell lung cancer 
(NSCLC) [15, 22,23, 24].  Proliferation can occur via alternative epigenetic mechanisms 
whereby the nitrosamine ligates with nicotinic acetylcholine receptors (nAChRs) located 
on the surface of epithelial cell membranes.  These receptors are integral membrane 
proteins formed by the assembly of five trans-membrane subunits (α3, α5, α7, β4) and 
exist in either homomeric or heteromeric forms [1]. (Figure 1.3)  NNK binding causes a 
conformational change in the receptor, which induces a channel within the membrane to 
open, allowing for the influx of Na+ and Ca+2 ions.  Simultaneously, the efflux of K+ ions 
occurs, resulting in membrane depolarization and the opening of voltage-gated Ca+2 
channels.  This influx of Ca+2 leads to enhanced activity in signaling pathways such as 
Protein Kinase C and A, Ras and PI3K, resulting in cell proliferation, angiogenesis, and 
apoptotic inhibition [25,26].  Figure 1.4 
 
 
Figure 1.3- Nicotinic Acetylcholine Receptors [27] 
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Figure 1.4- Signaling Pathways Activated by NNK 
[http://dx.doi.org/10.1016/j.jecm.2011.10.003] 
 
 
 
1.1.4 Neurobiological Effects of Nicotine 
Considering all the facts and statistics pertaining to the detrimental effects of 
tobacco use, many individuals still succumb to this habit, and either refuse or are unable 
to quit.  Out of the number of people that make the attempt, less than 5% are actually 
successful and only about one fifth of these individuals remain abstinent in the long run 
[28,1].  One of the reasons for this is that nicotine, the main component of tobacco, is 
extremely addictive.  Once nicotine is inhaled, it rapidly passes through the blood brain 
barrier and binds to nicotinic acetylcholine receptors, leading to the activation of the 
“reward” circuitry of the brain and subsequent release of chemicals such as dopamine, 
glutamate and GABA.  These chemicals elicit feelings of relaxation and euphoria.  Long-
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term usage of nicotine eventually results in neurobiological changes that lead to tolerance 
and addiction [29,30].  The effects of nicotine are so powerful and consuming that the 
overall experience is often compared to the effects elicited during use of hardcore drugs 
of abuse, i.e. cocaine and heroin [28].   
 
1.1.5 Tobacco Harm Reduction 
In the past few years, some public health officials have turned to tobacco harm 
reduction as an alternative means to reduce an individual’s exposure to adverse chemicals 
and toxins within tobacco products.  According to the American Council on Science and 
Health, tobacco harm reduction can be defined as “the substitution of far safer sources of 
nicotine by those smokers who are unable or unwilling to achieve nicotine/tobacco 
abstinence”.  In countries such as Sweden, the use of snus, a moist powdered tobacco that 
is a variant of dry snuff, contains significantly lower levels of nitrosamines and has 
resulted in a marked decrease in cigarette smoking and the number of tobacco-related 
deaths among both men and women [31].  An epidemiological study done by Gartner in 
2007 claimed that the health benefits from switching to low nitrosamine smokeless 
tobacco products are nearly as large as those from quitting tobacco use altogether [32].  
In 2011, Rodu provided evidence, based on a comprehensive review of existing scientific 
and medical literature, that smokeless tobacco products on average have significantly less 
toxins and the risk of developing lung cancer is essentially abolished, making their use 
90% safer than that of cigarettes [33].  In 2002, the Royal College of Physicians of 
London stated that the consumption of smokeless tobacco is 10-1,000 times less 
hazardous than smoking [33].  PREPs (non-combustible potential reduced exposure 
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products), have also been developed to reduce harmful tobacco exposure and include 
compressed tobacco tablets, nicotine water and patches, medicinal nicotine products and 
low nitrosamine cigarettes and smokeless tobacco products [34,35]. Although these 
products have been shown to be effective, many long-term tobacco users fail to quit 
because of the overpowering addictive properties of nicotine.  Reduced exposure 
products that do not interfere with the free passage of nicotine within the brain would 
potentially save millions of lives worldwide. 
 
1.1.6 Monoclonal Antibodies 
In order to investigate alternative means for tobacco harm reduction, certain 
immunotherapies focused on mitigating the effects of debilitating drugs of abuse are 
currently in development.  One such therapy involves the passive administration of poly- 
or monoclonal antibodies specific for drugs such as nicotine, heroin, cocaine and 
methamphetamine [36].  These antibodies are particularly effective due in part to their 
small molecular size, allowing for extensive tissue distribution and long elimination half-
life following administration [37].  In 2009, Roiko et al passively immunized mice with a 
monoclonal antibody against nicotine and was able to successfully reduce the levels of 
the chemical within the brain [38].  Another study conducted by Norman et al in 2007 
demonstrated that the intravenous administration of an anti-cocaine monoclonal antibody 
prior to the injection of cocaine was able to significantly decrease the levels of the 
substance within the brain of mice [39]. These are just a few of the many studies that 
highlight the potential for antibody-mediated interception as a therapeutic means to 
ameliorate or eliminate the toxicity associated with certain chemicals.  
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1.1.7 Recombinant Antibodies 
The production of recombinant antibodies that express high affinity binding sites 
have become particularly attractive for immune-mediated sequestration of harmful toxins 
and chemicals.  A way in which these sites can be created is through the use of 2A 
peptides derived from certain single-stranded RNA viruses.  These peptides, which are 
usually around 18 amino acids long, mediate autonomous intra-ribosomal self-processing 
of multiple proteins from a single open reading frame [40].  In the current study, a 2A 
peptide derived from Foot and Mouth Disease Virus (FMDV) was used specifically for 
this purpose.  The peptide originates from the viral family Picornaviridae, and functions 
by initiating “ribosomal skipping” at the glycin-proline peptide bond located within its 
highly conserved functional motif (D (V/I) EXNPGP) [41].  (Figure 1.5)  This results in 
interruption of peptide bond formation at this location, leading to cleavage of the 
upstream protein.  After this cleavage event occurs, translation of the downstream protein 
resumes (Figure 1.6).  All that remains of the 2A sequence on this protein in the proline.  
In order to remove the remainder of the 2A sequence from the upstream protein, a furin 
cleavage site is usually inserted just upstream of the sequence.  Upon cellular processing, 
the remainder of the sequence is removed at this site and what remains are equal 
concentrations of both the downstream and upstream proteins.  
 In the work described herein, the 2A peptide derived from FMDV was used to create 
an anti-NNK recombinant binding site. This approach enabled the parent hybridoma to be 
expressed as a single chain antibody fragment. This antibody format is beneficial because 
its smaller structure facilitates ease of cloning into expression vectors, elicits minimal 
immunogenicity and is rapidly cleared from the circulation [31]. Following production, 
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the recombinant antibody, delivered by the appropriate vector or admixed with the 
product, may be used to passively protect the oral cavity prior to or during smokeless 
tobacco use. NNK bioactivation will be prevented once the high-affinity antibody binds 
to its target and the complex is predicted to be harmlessly eliminated through 
expectoration. According to a study conducted by Hecht et al (2007), daily exposure of 
NNK in smokeless tobacco users is ~6 µg, when an average of 2 grams tobacco is 
chewed.  The study also found that the average concentration of NNK in expectorated 
saliva of 15 smokeless tobacco users was 3.2 nmol [42].  Based on these findings, tests 
will need to be conducted to determine the optimal molar concentration of binding 
fragment vs. NNK in saliva in order to elicit the desired protective response.  After the 
appropriate concentrations have been determined, the safety and efficacy of this approach 
will be tested in animal models and humans.  
  Another consideration that must be taken into account is the complex environment in 
which the recombinant binding fragment will be introduced.  The oral cavity contains 
many different cells responsible for maintaining homeostasis and initiating proteolytic 
degradation of food and foreign substances, some of which include lymphocytes, acinar 
cells, squamous epithelial cells and bacterial cells.  In addition to this, saliva also contains 
many different electrolytes, anti-bacterial compounds and several proteases [43].  Tests 
will be necessary to determine the extent to which these components may affect antigen-
antibody complex formation within the oral cavity. 
A long-term goal of the current proposal is to produce transgenic tobacco that allows 
the free passage of nicotine from the product, but blocks the bioavailability of 
carcinogens like NNK by immuno-interception. The expression of recombinant 
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antibodies in tobacco has already proven to be technically feasible and will allow for the 
large-scale production of therapeutic antibodies at relatively low costs, making this 
approach particularly attractive to individuals seeking cost-effective tobacco harm 
reduction products.  
 
Figure 1.5: Highly Conserved 2A Sequences [44] 
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Figure 1.6:  Mechanism of Cleavage Event Initiated by Viral 2A Peptide  
Ribosomal skipping is initiated by the viral 2A peptide through interruption of the 
peptide bond between the glycine and proline that are located within its highly conserved 
functional motif. 
  
http://www.google.com/imgres?imgurl=http://education.expasy.org/images/Ribskip.jpg&imgrefurl=http://v
iralzone.expasy.org/all_by_protein/914.html 
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Materials and Methods 
2.1.1 Cloning and Characterization of F(ab)-generating single chain antibody: 
Four T-75 culture flasks containing 7F cells in Hybricare Media supplemented with 
MEM Sodium Pyruvate (100 mM), MEM Non-essential AA (10 mM), L-Glutamine (200 
mM), 1× AB/AM and 20% heat inactivated FBS were sent to Creative Biolabs (Shirley, 
NY, USA) for amplification and sequencing. An intervening 2A motif derived from 
FMDV was cloned into the expression vector 7Fmab_pFab-HL via restriction enzymes 
EcoRI and NotI. The amplified VH and VL Immunoglobulin chains of the antibody 
flanked the peptide linker and a furin cleavage site was inserted just upstream of the 2A 
motif. The construct was transfected into HEK293 cells to allow for cleavage and 
subsequent expression of the recombinant binding fragment.  Under denaturing 
conditions, an SDS-PAGE was performed according to [45] in order to verify cleavage 
and the appropriate molecular weight of the polyprotein. Next, a Western Blot was 
performed to test the protein’s immunoreactivity to a Fab-specific antibody. The primary 
antibody used was an Anti-Mouse IgG (Fab-specific) conjugated to alkaline phosphatase 
(Sigma-Aldrich, St. Louis, MO, USA) and diluted 1:10,000 in PTA/BSA 0.1% buffer 
(0.05 M phosphate buffer saline (PBS) + tween 20 (Aldrich, Milwaukee, WI, USA) + 
0.01% sodium azide (Fluka, Buchs Sg, Switzerland)), with 0.1% ovalbumin added to the 
buffer pH 7.4. A second Western Blot was performed using a 1:40,000 dilution of the 
Anti-Mouse IgG (Fab-specific) antibody in order to better visualize the Immunoglobulin 
chains.    
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2.1.2   ELISA of F(ab): 
ELISA was performed to test the binding of the F(ab) to its target antigen (NNK). One 
96-well plate was coated with 10 µg/mL NNKB-Ovalbumin and 10 µg/mL Ovalbumin. 
Each of the coating solutions were diluted in 0.05 M sodium carbonate buffer (Sigma-
Aldrich Inc. St. Lous, MO, USA), pH 9.6. The plate was wrapped in two layers of 
Parafilm and incubated at room temperature (21 °C) overnight. The next morning, a 1:8 
dilution of the protein was made in PTA/BSA 0.1% buffer. A 1:2500 dilution of 7F was 
also made up to test on the same plate in order to compare the binding efficacies of the 
complete IgG versus the anti-NNK binding fragment. After the solutions were mixed, the 
96-well plate was washed five times with PTA/BSA 0.1% buffer using a Bio-Tek 
ELx405 Microplate Washer. The plate was then blotted dry on paper towels. Fifty 
microliters/well of each antibody was added to their corresponding locations within the 
plate. The plate was then placed at room temperature for overnight incubation. The 
following morning, the plate was washed three times in PTA/BSA 0.1% buffer and 
blotted dry as above. A 1:1,000 dilution of Polyvalent Anti-Mouse IgG, A, M antibody 
conjugated to Alkaline Phosphatase was made up for application to the wells containing 
the 7F antibody. A 1:10,000 dilution of anti-Mouse IgG (Fab-specific) antibody 
conjugated to Alkaline Phosphatase was made for application to the wells containing the 
F(ab). Fifty microliters of each solution was then added to the appropriate wells. After a 
two hour incubation at room temperature the plate was washed 3 times once again using 
PTA/BSA 0.1% buffer. Two 5 mg tablets of the phosphatase substrate PNPP (Sigma-
Aldrich, Lot # 120N8201V, St. Louis, MO, USA) were diluted in 10 mL of 0.05 M 
sodium carbonate + 0.001 M magnesium chloride (Sigma-Aldrich Inc. St. Louis MO, 
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USA) pH 9.8 and 50µL of this mixture was added to each of the wells. Results were then 
read at 25, 50, and 100 min using a Bio-Tek uQuant Universal Microplate 
Spectrophotometer set at a wavelength of 405 nm (Biotek Instruments, Winooski, VT, 
USA). 
 
2.1.3 Competitive ELISA of F(ab): 
A competition ELISA using the F(ab) was performed with NNK as the soluble 
competitor. The monoclonal antibody 7F was used as a positive control. A stock solution 
of NNK was made at a concentration of 48.25 mM (10 mg/mL) in de-ionized water. This 
solution was then diluted to 966 µM, 292 µM, 88.0 µM and 26.0 µM. 125 µL of each 
dilution of NNK was added to separate test tubes, which contained 125uL of either a 1:4 
dilution of F(ab) or a 1:1250 dilution of 7F. The samples were then mixed and incubated 
at room temperature for 30 min in order to allow for appropriate competition to occur. 50 
µL of each test tube containing the samples were added to their corresponding wells. 
After a 2 hr incubation period, plates were washed three times as above. A 1:10,000 
dilution of anti-Mouse IgG (Fab-specific) antibody conjugated to Alkaline Phosphatase was 
then applied to the F(ab)-containing wells and a 1:1,000 dilution of Anti-Mouse IgG, A, M 
antibody conjugated to Alkaline Phosphatase was applied to 7F-containing wells, each at 
a volume of 50 µL/well. Plates were then washed as above followed by PNPP substrate 
addition. Results were read at 25, 50 and 100 min intervals with the Bio-tek 
spectrophotometer set at a wavelength of 405 nm.  
.  
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2.1.4 Cell Viability Assay: 
 
To test the ability of the F(ab) to block the harmful effects of NNK on susceptible 
cells, the lung adenocarcinoma cell line A549 was purchased from ATCC.  Cells were 
grown in F-12K media supplemented with 10 % FBS and 1x Ab/Am.  Media was 
changed every 2-3 days and cells were passaged when they reached 70-80% confluency.  
To determine cell viability after exposure to NNK, cells were transferred to an opaque 
96-well plate at a density of 6 x 10³ cells per well.  After 24 hours in F-12K media 
supplemented with 10% FBS, media was switched to 0.05% FBS to remove any 
exogenous growth factors that would affect the interaction of NNK with the cells.  A 10 
mg/mL stock solution of NNK was diluted to 2,500 µg/mL, 250 µg/mL, 25 µg/mL, 2.5 
µg/mL and 0.25 µg/mL in F-12K media containing 0.05% FBS.  After another 24 hours, 
the NNK solutions were added at 100 µL/well to the plate.  Cell viability of the cells was 
determined 24 hours later by performing a Cell Titer Glo Assay.  Results were read on a 
FluoStar Optima Luminometer from BMG Labtech (Cary, NC, USA) at 45 minutes post 
application of the Cell Titer Glo reagent per manufacturer’s protocol. 
 
2.1.5   BrdU Proliferation Assay: 
 A BrdU Proliferation Assay was performed in order to determine the effect of 
NNK on transformed lung epithelial cells in vitro.  NCI-H441 cells were purchased from 
ATCC and grown in RPMI-1640 media supplemented with 10% FBS and 1x Ab/Am.  
Media was changed every 4-5 days and cells were passaged when they reached 70-80% 
confluency.  To determine cell proliferation after exposure to varying concentrations of 
NNK, freshly trypsinized cells dilute either 1:10 or 1:15 in fresh RPMI-1640 media 
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supplemented with 10% FBS and 1x Ab/Am, were seeded in 96-well plates at a density 
of 5 x 103/well.  Plates were then covered and placed in 37°C, 5% CO2 for 24 hrs.  The 
following day, cells were serum-starved to remove any exogenous growth factors by 
replacing media with 0.12% FBS.  Cells were then placed in 37°C, 5% CO2 for an 
additional 24 hrs.  After cells reached 30% confluency, 10-fold serial dilutions of NNK 
(10mg/mL) mixed with RPMI-1640 media supplemented with 0.12% FBS were added to 
corresponding wells (0.483 µM, 4.83 µM, 48.3 µM, 483 µM, and 4,830 µM NNK).  
Control wells contained cells mixed with RPMI-1640 media supplemented with 0.12% 
FBS and no NNK.  Plates were placed in 37°C, 5% CO2 for a 2 hour incubation period.  
 20 µL/well of BrdU reagent was then added to the appropriate wells and cells 
were incubated for a total of 24hrs.  Cells were then fixed and denatured according to the 
manufacturer’s protocol.  Wash buffer was added to the plates for a total of three times, 
aspirated after the final wash and blotted dry on paper towels.  100 µL/well of anti-BrdU 
monoclonal antibody was then added to the appropriate wells and incubated at room 
temperature for 1 hour.  Plates were washed as above and blotted dry on paper towels.  
Goat anti-Mouse IgG, Peroxidase Conjugate was added at 100 µL/well and incubated at 
room temperature for a total of 30 min.  Plates were once again washed 3 times and 
blotted dry on paper towels.  100 µL/well of TMB Peroxidase Substrate were added to 
corresponding wells and incubated at room temperature in the dark for 30 min.  After the 
30 min. incubation period, 100 µL/well of the acid Stop Solution was pipetted into the 
appropriate wells.  Positive wells which corresponded to proliferating cells changed from 
blue to bright yellow.  Results were read using a Bio-Tek uQuant Universal Microplate 
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Spectrophotometer set at a wavelength of 490 nm (Biotek Instruments, Winooski, VT, 
USA). 
 
2.1.6 Reconstruction of Plasmid Encoding Anti-NNK Recombinant Binding 
Fragment 
Using the previously cloned antibody sequence, adjustments were made to the 
first plasmid vector (7F Fab) to improve overall binding affinity of the anti-NNK 
recombinant binding fragment.  7F VL-CL DNA was amplified from the 7F Fab vector 
using the primers U7fvl/Dck and ligated into pUC57 via PstI/MfeI, yielding the vector 
designated as pUC57s-7FVLCL. 7F VH-CH1 DNA was then amplified from the 7F Fab 
vector using the primers U7fvh/Dch1 and ligated into pUC57-7FVLCL via SacII/AvrII. 
The identity of the sequences was verified by DNA sequencing. The final vector was 
designated as pUC57s-7FHL.  The plasmid was amplified via bacterial transformation in 
E.Coli Top10 competent cells.   
 
2.1.7 Validation of Plasmid Vector Sequence   
 Before transcription/translation of the plasmid was performed, the DNA was re-
sequenced to confirm proper identity.  E-Coli Top10 competent cells containing the 
plasmid vector, sent initially from Creative Biolabs, were streaked onto LB agar plates 
containing ampicillin and grown overnight at 37°C. Single colonies were inoculated in 3-
5 mL LB broth containing ampicillin and incubated for 16-18 hrs in a 37° C shaking 
incubator.  The following day, plasmid was purified using a Qiagen Plasmid Mini Prep.  
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The appropriate primers were purchased and the DNA was amplified using PureTaq 
ready to go PCR beads from Fisher Scientific.  
 Restriction Digests were then performed to verify proper molecular weight of the 
vector.  5 µL NeBuffer EcoRI + 0.5 µL BSA + 33.5 µL ddH20 + 10 µL DNA template 
(22.3 ng/ µL) + 1 µL EcoRI were added to a 1.5 mL vial to linearize the plasmid.  1 µL 
EcoRI and 1 µL Not I were then added to 5 µL NeBuffer EcoRI + 0.5 µL BSA + 32.5 µL 
ddH20 + 10 µL DNA template (22.3 ng/ µL) in order to confirm proper molecular weight 
of the insert.  5µL NeBuffer EcoRI + 0.5 µL BSA, 32.5 µL ddH20 + 10 µL PCR product 
+ 1 µL each of enzymes Eco RI and Not I were then added to a 1.5 mL vial.  Each of the 
three samples were then mixed gently and placed at 37°C for 2 hours.  Agarose gel 
analysis was performed and amplified DNA fragments resembling the insert were cut out 
from the gel and purified using a Qiaquick Gel Extraction Kit from Qiagen.  Final 
product was sent out for sequencing.        
 
2.1.8 Coupled Transcription/Translation of Purified Plasmid 
 For expression of the anti-NNK recombinant binding fragment, a TNT T7 Quick 
Coupled Transcription/Translation System from Promega was used.  DNA was purified 
and then concentrated using a DNA Clean & ConcentratorTM-5 Kit from Zymo Research.  
Circular and linearized DNA templates were tested to determine which structure was 
most ideal for optimal protein expression.  Final concentration of circular and linearized 
DNA used in the coupled transcription/translation reaction was 0.87 µg and 0.45 µg, 
respectively.  20 µL TNT master mix, 0.5 µL 1mM Methionine, 4 µL DNA template 
(circular plasmid) and 0.5 µL Canine Pancreatic Microsomal Membranes were added to 
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a 1.5 mL tube on ice and vortexed gently to properly mix.  20 µL TNT master mix, 0.5 
µL 1 mM Methionine, 0.5 µL T7 PCR Promoter enhancer, 4 µL DNA template 
(linearized plasmid) and 0.45 µL Canine Pancreatic Microsomal Membranes were added 
to a 1.5 mL tube on ice and mixed as above.  The samples were then placed at 30° C for a 
total of 75 minutes per manufacturer’s protocol.   
 
2.1.9 Purification of Final Protein Product 
 After coupled transcription/translation of the linearized and circular plasmid was 
performed, the polyhistidine-tagged binding products were purified using the MagZTM 
Protein Purification System from Promega.  50 µL circular and 50 µL linearized plasmid 
from the coupled transcription/translation reaction were each applied to two empty 1.5 
mL vials.  100 µL each MagZ Binding/Wash Buffer was then added and vials were 
mixed by inverting slowly 5 times.  Two 40 µL aliquots of MagZ Binding Particles were 
then transferred to two empty 1.5 mL vials.  Each tube was placed in a magnetic stand to 
allow for separation of binding particles from the supernatant.  Next, each prepared 
protein solution from above was added to the vials containing the binding particles.  The 
mixtures were carefully pipetted to re-suspend the particles in solution.  The solutions 
were then incubated for 15 minutes at room temperature with gentle agitation to avoid 
settling of particles at bottom of tubes.   
 Supernatant from each vial was then removed by placing the vials in the magnetic 
stand in order to separate the beads from the mixture.  200 µL MagZ Binding/Wash 
buffer was added to the particles and mixed by pipetting 5-6 times.  Tubes were placed in 
the magnetic stand once again to facilitate supernatant removal.  This wash step was 
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repeated 3 additional times.  100 µL each of Elution Buffer was added to washed beads in 
both vials and mixed five times.  Purified protein product was obtained by placing the 
vials in the magnetic stand and removing the supernatant.  
 
2.1.10 Protein Concentration 
 Purified protein products were concentrated using a Protein Concentrate (Micro) 
Kit from Millipore (Temecula, Ca).  50 µL of each sample were added to two vials 
containing 150 µL each of UPPA-1 Buffer and incubated on ice for 15 minutes.  150 µL 
UPPA-II buffer was then added, vials were vortexed and placed in a table top 
microcentrifuge at 10,000 rpm for 5 minutes.  Supernatant was discarded and the pellets 
were each covered with 40 µL UPC-Wash and centrifuged at 10,000 rpm for 5 minutes.  
Supernatant was collect and 25 µL RNAse free water was added to each of the protein 
pellets.  Vials were centrifuged at 10,000 rpm for 30 seconds.  700 µL pre-chilled 
Orgosol buffer and 3 µL UPC-Seed was added to each vial, vortexed and then placed at  
-20° C for 30 minutes.  During this period, vials were mixed intermittently for a total of 
20 seconds at each time interval.  Vials were then centrifuged once again at 10,000 rpm 
for a total of 5 minutes.  The supernatant was collected and 15 µL Precipitate Buffer I 
was added to each vial.  After a 2 minute incubation on ice, 3 µL Precipitate Buffer II 
was added to both vials.  Samples were then incubated for 5 minutes on ice and 
centrifuged at 10,000 rpm for a total of 30 seconds.  Clear supernatant containing the 
concentrated protein product was collected from each vial.   
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2.1.11 Re-Characterization of F(ab)-generating single chain antibody: 
 SDS-PAGE was performed to verify proper translation of the protein product.  20 
µL purified protein product + 3 µL NuPAGE denaturing agent + 7.5 µL SDS-PAGE 
reagent were added to a 10% polyacrylamide pre-packaged gel from NuPAGE.  Proteins 
were resolved by running the reaction at 150 V for a total of 30 minutes.  The gel was 
then stained using a Silver Staining Kit from Life Sciences in order to visualize the 
protein bands. 
 
2.1.12 Western Blot Analysis 
 Protein bands were transferred to a PVDF membrane by running a Western Blot 
at 30 V for 60 minutes at 4 degrees Celsius.  The membrane was incubated in 5% non-fat 
dry milk + TBS-T for one hour and then incubated with a 1:5,000 dilution of an anti-
mouse IgG (Fab-specific) alkaline phosphatase conjugated antibody in blocking buffer, 
for a total of two hours.  The membrane was then washed in TBS-T according to protocol 
and bands were developed by using a SIGMAFAST™ BCIP®/NBT tablet from Sigma-
Aldrich.     
 
2.1.13   Statistical Analysis 
Statistical analysis was performed on data obtained from the F(ab) and 7F 
Competition ELISA.  Using SAS 9.2 for Windows, the significance level α was set to 
0.05% and a Mixed Procedure with a Diagonal Covariance Structure was performed. 
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Results 
The mRNA from the 7F hybridoma VH and VL coding sequence was converted to 
cDNA, amplified, (Figure 3.1.1) sequenced and cloned into an expression vector with the 
FMDV 2A cleavage motif placed in-frame and between the two fragments (Figure 
3.1.2). The resulting expression vector was used to transfect HEK293 cells to determine 
if a functional F(ab) was synthesized and secreted. Concentrated tissue culture 
supernatants were purified over an affinity column and the eluate analyzed by SDS-PAGE, 
which confirmed that the sequence was successfully translated, cleaved and secreted 
(Figure 3.1.3). Western Blots confirmed the presence of the heavy and light chain 
fragments at the predicted molecular weights, however a stronger band was observed for 
the 24 kD fragment (Figure 3.1.4). Competition studies using the anti-NNK binding 
fragment showed a concentration dependent inhibition of binding upon pre-incubation 
with free NNK, reaching 85% at the highest concentration tested (0.48 mM) (Figure 
3.1.5). 
Both a cell viability assay and proliferation assay were performed to determine 
the effects of NNK on transformed lung epithelial and adenocarcinoma cells.  Results 
were inconclusive in that both A549 and NCI-H441 cells did not respond to varying 
concentrations of NNK (0.483 µM-4,830 µM) over an incubation period of 19-48 hrs.   
In order to improve the binding affinity of the previously expressed F(ab), several 
adjustments were made to the initial plasmid constructed by Creative Biolabs.  To the 
amplified VL/VH DNA sequence containing the FMDV 2A cleavage motif, a T7 
Promoter, Kozak Sequence, ER cleavable signal sequence from Calreticulin, GSG 
Linker, His Tag and Synthetic Poly A tag plus suitable endonuclease enzyme sites were 
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added.  All of these components were cloned into the expression vector pUC57 in order 
to yield the final product (Figure 3.1.6).  The plasmid was sequenced (Figure 3.1.7), and 
then amplified for subsequent expression in a coupled transcription/translation cell-free 
system.  The sequence of the plasmid was re-confirmed by performing Restriction 
Digests.  Agarose Gel Analysis (Figure 3.1.8) confirmed that the plasmid amplified from 
E-Coli TOP10 transformed bacterial cells was in fact the correct Molecular Weight (4.2 
Kb), and that digestion of the plasmid with enzymes NotI and EcoRI produced an insert 
of the anticipated size (1.6 Kb).  SDS-PAGE analysis was inconclusive due to the 
presence of several protein bands of various molecular weights (Figure 3.1.9).  These 
bands are most likely part of the rabbit reticulocyte lysate from the coupled 
transcription/translation reaction that were co-purified with the protein.  In order to 
confirm that proper protein processing occurred, a Western Blot was performed using a 
1:5000 dilution of an anti-mouse IgG (Fab-specific) antibody.  Development of the 
PVDF membrane showed that protein bands were not present.  
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Figure 3.1.1: PCR amplification of the VH and VL Immunoglobulin chains of the 7F 
Mab.  
 
mRNA from the 7F hybridoma was converted to cDNA and then amplified via PCR. 
Results showed two individual bands of the appropriate molecular weights. LANE 1: 
PCR amplification of the VL with the κ primers; LANE 2: PCR amplification of the VH 
with the VH back primers and CH1 for primers; M: molecular weight standard. 
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Figure 3.1.2: The schematic map of BSA-DP-pFab-H 
 
The BSA-DP-pFab-H eukaryotic expression vector was expressed within HEK293 cells.  
The DNA of the individual Ig chains, linked by the 2A sequence, was cloned into the 
vector via EcoRI/NotI. 
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Figure 3.1.3: SDS-PAGE separation of purified Anti-NNK Binding Fragment 
 
 
A non-denaturing SDS-PAGE revealed that expression of the F(ab) in HEK293 cells 
resulted in the successful cleavage of the fusion product into two individual 
Immunoglobluin chains at the anticipated molecular weights 
  
 
M: Molecular Weight standard 
Lane 1: Cleaved VL and VH antibody chains 
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Figure 3.1.4: Western Blot   
 
Western Blot analysis of the binding fragment expressed in HEK293 cells revealed the  
 
presence of two protein bands at the anticipated molecular weights.  An anti-mouse IgG  
 
(Fab-specific) alk. phos. conjugated Ab was used at a 1:40,000 dilution for detection of  
 
the individual Immunoglobulin chains. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 M: Molecular Weight Standard 
 Lane 1: VH and VL Immunoglobulin Chains at 1:40,000 dilution of primary Ab. 
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Figure 3.1.5:   Competitive Inhibition of Anti-NNK Binding Fragment and 7F using 
free NNK 
A 10 mg/mL stock solution of NNK was diluted to initial concentrations of 26 µM, 88 
µM, 292 µM, and 966 µM. A 1:4 dilution of the F(ab) was added to each concentration of 
NNK to yield a final dilution of 1:8. Competition ELISA screening revealed that 
approximately 84% inhibition of the construct was seen at 483 µM of NNK. At the same 
concentration of NNK, 85% inhibition of the monoclonal antibody 7F was evident. 
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Figure 3.1.6: Final Plasmid Construct 
7F VL-CL DNA was amplified from the original 7F Fab vector using the primers 
U7fvl/Dck and ligated into pUC57s via PstI/MfeI, yielding the vector designated as 
pUC57s-7FVLCL. 7F VH-CH1 DNA was amplified from the 7F Fab vector using the 
primers U7fvh/Dch1 and ligated into pUC57s-7FVLCL via SacII/AvrII. The identity of 
the sequences were verified by DNA sequencing (Figure 3.1.7). The final vector was 
designated as pUC57s-7FHL. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
pUC57s-7FHL
4247 bp
Kozak seq
ER cleavable s ignal seq
CH1
Furin s ite
GSG linker
2A seq
ER cleavable s ignal seq
CL
His6
7F VH
7F VL
Ampr
polyA
Pt7
Eco RI (398)
Not I (2000)
Avr II (1147)
Mfe I (1913)
Sac II (482)
Pst I (1025)
Pst I (1299)
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Figure 3.1.7: DNA sequence of Optimized Anti-NNK Binding Fragment 
Purple = T7 Promoter 
Underlined = Kozak Sequence 
Yellow = ER cleavable signal sequence from Calreticulin 
Light Green = Variable Heavy Chain 
Light Blue = Constant Heavy Chain 
Dark Yellow = Furin Site 
Teal = GSG Linker 
Grey = 2A sequence 
Pink = Variable Light Chain 
Red = Constant Light Chain 
Green = His Tag 
Dark Grey = Synthetic Poly A tag 
 
                                                                 
       1 CGA ATT CGA CTA ATA CGA CTC ACT ATA GGG AGA GCC ACC ATG CTG CTC CCT GTG CCG CTG  
      61 CTG CTC GGC CTG CTC GGC CTG GCC GCG GCC GAG GTG AAG CTG GAT GAG ACT GGA GGA GGC  
     121 TTG GTG CAA CCT GGG AGG CCC ATG AAA CTC TCC TGT GTT GCC TCT GGA TTC ACT TTT AGT 
     181 GAC TAC TGG ATG AAC TGG GTC CGC CAG TCT CCA GAG AAA GGA CTG GAG TGG GTA GCA CAA 
     241 ATT AGA AAG AAA CCT TAT AAT TAT GAA ACA TAT TAT TCA GAT TCT GTG AAA GGC AGA TTC  
     301 ACC ATC TCA AGA GAT GAT TCC AAA AGT AGT GTC TAC CTG CAA ATG AAC AAC GTA AGA GCT  
     361 GAA GAC ATG GGT ATC TAT TAC TGT ACG GCC TAT GGT TAC GAC GAT TAC TAT ACT ATG GAC  
     421 TAC TGG GGT CAA GGA ACC TCA GTC ACC GTC TCC TCA GCC AAA ACG ACA CCC CCA TCT GTC  
     481 TAT CCA CTG GCC CCT GGA TCT GCT GCC CAA ACT AAC TCC ATG GTG ACC CTG GGA TGC CTG 
     541 GTC AAG GGC TAT TTC CCT GAG CCA GTG ACA GTG ACC TGG AAC TCT GGA TCC CTG TCC AGC 
     601 GGT GTG CAC ACC TTC CCA GCT GTC CTG CAG TCT GAC CTC TAC ACT CTG AGC AGC TCA GTG 
     661 ACT GTC CCC TCC AGC ACC TGG CCC AGC GAG ACC GTC ACC TGC AAC GTT GCC CAC CCG GCC 
     721 AGC AGC ACC ACG GTG GAC AAA AAA ATT GTG CCT AGG GAT TGT AGG AAG AGG CGA GGA TCC 
     781 GGA GCA CCT GTA AAG CAA ACA CTG AAC TTT GAC CTT CTC AAG TTG GCT GGA GAC GTT GAG 
     841 TCC AAT CCT GGG CCC ATG CTG CTC CCT GTG CCG CTG CTG CTC GGC CTG CTC GGC CTG GCT 
     901 GCA GCC GAC ATT GTG ATG ACC CAG TCT CAA AAA TTC ATG TCC ACA TCA GTA GGA GAC AGG 
     961 GTC AGC ATC ACC TGC AAG GCC AGT CAG AAT GTT CGT ACT GCT GTA GCC TGG TAT CAA CAG 
    1021 AAA CCA GGG CAG TCT CCT AAA GCA CTG ATT TAC TTG GCA TCC AAC CGG CAC ACT GGA GTC 
    1081 CCT GAT CGC TTC ACA GGC AGT GGA TCT GGG ACT GAT TTC ACT CTC ACC ATT AGC AAT GTG 
    1141 CAA TCT GAA GAC CTG GCA GAT TAT TTC TGT CTG CAA CAT TGG AAT TAT CCG TAC ACG TTC 
    1201 GGA GGG GGG ACC AAG CTG GAA ATA AAA CGG GCT GAT GCT GCA CCA ACT GTA TCC ATC TTC 
    1261 CCA CCA TCC AGT GAG CAG TTA ACA TCT GGA GGT GCC TCA GTC GTG TGC TTC TTG AAC AAC 
    1321 TTC TAC CCC AAA GAC ATC AAT GTC AAG TGG AAG ATT GAT GGC AGT GAA CGA CAA AAT GGC 
  1381   GTC CTG AAC AGT TGG ACT GAT CAG GAC AGC AAA GAC AGC ACC TAC AGC ATG      AGC    AGC   
ACC 
    1441 CTC ACG TTG ACC AAG GAC GAG TAT GAA CGA CAT AAC AGC TAT ACC TGT GAG GCC ACT CAC  
    1501 AAG ACA TCA ACT TCA CCA ATT GTC AAG AGC TTC AAC AGG AAT GAG TGT CAC CAC  
 CAC CAC 
    1561       CAC CAC TAA AAA AAA AAA AAA AAA AAA AAA AAA AAA AAA TGA GCG GCC GCT C 
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Figure 3.1.8: Gel Analysis of DNA from Reconstructed Plasmid 
 
An agarose gel was run to confirm the identity of the pUC57s-7FHL expression vector.  
Restriction digests were performed using enzymes EcoRI and NotI.  Gel analysis 
revealed that the vector contained the insert and at the appropriate molecular weight.   
 
         
       M    1    2    3     4     5    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
M:  Molecular Weight Marker 
Lane 1: Supercoiled Plasmid 
Lane 2: Linearized Plasmid  
Lane 3: Empty Plasmid + Insert 
Lane 4: PCR Amplified Insert 
Lane 5: PCR Amplified Insert 
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Figure 3.1.9: SDS-PAGE of Anti-NNK Binding Fragment 
 
  SDS-PAGE analysis was performed on the binding fragment expressed within the 
coupled transcription/translation system.  Results portrayed the presence of several 
different protein bands at varying molecular weights, along with two bands at the 
anticipated molecular weights (25 kDa).   
 
 
        M       1               2 
 
 
 
 
 
75 kDa- 
 
50 kDa- 
37 kDa- 
 
25 kDa- 
 
 
 
 
Lane 1= Linearized Sample 
Lane 2= Supercoiled Sample 
M= Molecular Weight Marker 
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Discussion 
Immune-mediated sequestration of carcinogens and toxicants found in certain 
products is an attractive means to mitigate the harmful biological effects of these 
compounds.  The following proposal demonstrates the feasibility of this approach when 
combating the carcinogen NNK, which is abundant in smokeless tobacco.  Over the past 
few years, other studies have attempted to mitigate the acute toxicity effects of drugs 
such as cocaine, heroin, methamphetamine, colchicine, oleander and other related 
substances [26, 46, 47, 48].  This work builds upon these previous studies by attempting 
to create a high affinity recombinant anti-NNK binding site derived from a monoclonal 
antibody specific for NNK that was synthesized previously [49].  To increase the binding 
efficiency of the antibody fragment, an FMDV 2A peptide was cloned between the 
amplified VH and VL immunoglobulin chains of the monoclonal antibody.  The 
incorporation of this self-cleaving peptide between multiple proteins within a single 
vector has been shown to significantly improve protein expression and is superior to the 
IRES approach in regards to the ratios of each translated protein translated [40, 41, 50].   
Amplification and cloning of the VH and VL immunoglobulin chains derived from 
the 7F monoclonal antibody was successfully accomplished along with the incorporation 
of the 2A peptide linker.  When the construct was expressed in HEK 293 cells, the 
formation of a recombinant binding fragment with a similar binding affinity to NNK as 
its parent hybridoma (7F) was seen.  According to competition studies, there was about a 
one log loss in binding affinity.   
In order to address the loss in binding affinity, the initial plasmid containing the 
insert was reconstructed.  We hypothesized that the original signal peptide attached 
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upstream of the light chain may not have been removed upon cellular processing, thereby 
interfering with proper antibody folding.  This would also account for the higher 
concentration of the variable light chain as seen in Figure 3.1.4.  In the new construct, an 
ER cleavable signal sequence from calreticulin was placed upstream of both the heavy 
and light chains.  A study by Felipe et al. (2004) showed that the incorporation of this 
signal sequence resulted in proper subcellular localization of two processing products 
[51].  Another improvement was the addition of a Gly-Ser-Gly linker between the 
upstream protein and the 2A peptide.  Cleavage efficiency is significantly improved by 
incorporation of this linker due to increased flexibility and relaxation of unfavorable 
conformations [52,53,54, 55,56].  In order to express the protein in the TNT coupled 
Transcription/Translation Cell-Free system, a T7 promoter, Kozak sequence and 
synthetic poly A tag were also added to the plasmid vector.  The incorporation of a poly-
His tag to the C-terminus of the light chain facilitated purification of the translated 
protein product, which was accomplished by using the MagZ Protein Purifcation System 
from Promega.  Standard nickel-based resins that are usually used for purification of 
polyhistidine-tagged proteins were not used in this instance due to the fact that 
hemoglobin from the rabbit reticulocyte lysate binds to the resin, resulting in its co-
elution with the poly-histidine tagged protein.   
Results from this experiment were inconclusive due to the fact that the Coupled 
Transcription/Translation system failed to produce an anti-NNK binding fragment.  Since 
this cell-free system lacks microsomal membranes necessary for proper cellular 
processing and glycosylation of proteins, the addition of canine pancreatic microsomal 
membranes were necessary for protein expression.  However, it has been shown that 
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addition of these membranes can sometimes inhibit the transcription/translation process 
by up to 50%.  Since bacterial cells produced plasmid DNA at relatively small 
concentrations (20 ng/ µL), it is also possible that not enough DNA was used for the 
coupled transcription/translation reaction, but it is more likely that proper subcellular 
processing of the protein failed to occur.  Expression of the construct in HEK293 cells 
would overcome this obstacle since all necessary cellular components, including 
microsomal membranes, are available for proper protein production. Studies will be 
conducted in the future using this cellular system in order to properly express the anti-
NNK binding fragment.  
Exposure of transformed lung epithelial and adenocarcinoma cells (NCI-H441 
and A549) to varying concentrations of NNK produced inconclusive results. Cells did not 
respond to NNK, even when incubated with very high concentrations (4,830 µM).  This 
finding contradicts several others showing NNK to be a strong tumor-promoter, even in 
minute quantities [57, 58, 6, 59].  One reason for this could be the aberrant mutation of 
α7 nicotinic acetylcholine receptors within the cells due to high cell passage number, 
which would render them unresponsive to NNK.  As mentioned previously, NNK ligation 
with these receptors is essential to activation of primary transcription factors necessary 
for the promotion of cellular proliferation/differentiation.  Another possible reason for 
this finding could be inactivation of the NNK itself.  NNK is sensitive to light/ UV 
exposure and if pH conditions are not optimal, can break down rather easily.  Future 
studies need to be conducted in order to test the validity/reliability of these results.   
 The current study provided proof of principal for the ability of a recombinant 
binding fragment derived from an anti-NNK monoclonal antibody to successfully 
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sequester the carcinogen.  This work paves the way for potential tobacco harm reduction 
immunotherapeutics that may one day be marketed in order to provide a less hazardous 
product for long-term tobacco users. 
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